DCN

Decorin (DCN) is a secreted extracellular matrix proteoglycan that governs collagen fibril organization and acts as a multifunctional signaling modulator restraining fibrosis and tumor progression (PMID:36534610). Frameshift mutations in DCN cause congenital stromal corneal dystrophy, where loss of normal protein disrupts lamellar collagen spacing and fibril formation in the corneal stroma, establishing its structural role in matrix assembly (PMID:36534610); DCN similarly promotes ordered collagen fibril organization during tendon healing (PMID:41313163). As a signaling molecule, DCN functions as an antagonist of EGFR and downregulates receptor levels in tumor cells (PMID:18520035), and its restoration in carcinoma cells and stromal fibroblasts suppresses proliferation, invasion, and metastasis while inducing P21 and E-cadherin and reversing cancer-associated fibroblast activation through STAT3/AUF1 signaling (PMID:26547587, PMID:38667295). DCN suppresses myofibroblast activation and pro-fibrotic gene expression, consistent with an anti-fibrotic function. In injured and stressed tissues DCN engages cytoprotective and immune programs: it is released from ferroptotic cells via secretory autophagy and lysosomal exocytosis and binds the macrophage receptor AGER to trigger NF-kB-dependent pro-inflammatory cytokine production as a damage-associated molecular pattern (PMID:34964698), and it promotes autophagy-mediated clearance of intracellular H. pylori (PMID:39145305). DCN expression is controlled at multiple levels: transcriptionally activated by EGR3 binding to its promoter (PMID:40660758) and by AhR recruitment that is blocked by +58CpG methylation (PMID:24424784), and post-translationally destabilized by OTUB1-mediated ubiquitination and proteasomal degradation (PMID:22279542).

1. 2008 Low

   Established that DCN can act as an EGFR antagonist, providing a molecular basis for its tumor-suppressive effect on proliferation.

   Evidence Recombinant SDF-1/54-DCN chimera in vitro assays on tumor cell proliferation and chemotaxis

   PMID:18520035

   Open questions at the time

   • No direct mechanistic dissection of DCN-EGFR binding separate from the chimera context
   • EGFR downregulation mechanism (degradation vs. internalization) not resolved
   • No in vivo validation of the DCN-EGFR axis
2. 2012 Medium

   Identified a post-translational control point showing DCN protein levels are limited by OTUB1-driven ubiquitination and degradation.

   Evidence Co-IP and OTUB1 overexpression with DCN ubiquitination/degradation assays in rat mesangial cells

   PMID:22279542

   Open questions at the time

   • Reciprocal/endogenous validation of the OTUB1-DCN interaction not shown
   • DCN ubiquitination sites and E3 ligase not identified
   • Physiological consequences in glomerulonephritis only correlative
3. 2014 Medium

   Defined an epigenetic mechanism whereby +58CpG methylation reduces AhR-driven DCN transcription, linking DCN loss to enhanced TGF-beta/Smad3 signaling and metastasis.

   Evidence Bisulfite sequencing, ChIP, EMSA, luciferase reporter, and 5-Aza treatment in NSCLC cells

   PMID:24424784

   Open questions at the time

   • Direct demonstration that DCN protein restoration reverses Smad3 activation not shown here
   • Whether AhR is the sole methylation-sensitive activator is unresolved
4. 2015 Low

   Showed DCN restoration suppresses carcinoma proliferation and metastasis with concomitant P21 and E-cadherin upregulation, framing DCN as a tumor suppressor.

   Evidence Ectopic DCN overexpression in RCC cells with in vitro assays and xenografts; Western blot

   PMID:26547587

   Open questions at the time

   • No mechanistic link between DCN and P21/E-cadherin induction
   • Receptor mediating these effects not identified
5. 2018 Low

   Demonstrated that DCN delivery shifts tumor signaling and immune polarization, modulating EMT, Wnt/beta-catenin, VEGF, Met, and Th1/Th2 cytokine balance.

   Evidence Oncolytic adenovirus rAd.DCN in an orthotopic breast tumor model with gene expression and cytokine analysis

   PMID:30032645

   Open questions at the time

   • Pathway placements are correlational, not direct mechanistic dissection
   • Direct DCN target receptor for each pathway unidentified
6. 2021 Medium

   Established DCN as a ferroptosis-derived DAMP that signals through the macrophage receptor AGER to drive NF-kB-dependent inflammation, defining a release-and-signal axis.

   Evidence Genetic and pharmacological inhibition of the DCN-AGER axis in cell culture and acute pancreatitis models

   PMID:34964698

   Open questions at the time

   • Structural basis of DCN-AGER binding not defined
   • Relative contribution of secretory autophagy vs. lysosomal exocytosis to release unresolved
7. 2022 Medium

   Provided direct human-genetics evidence that DCN loss-of-function causes congenital stromal corneal dystrophy via disrupted collagen fibril organization, cementing its structural ECM role.

   Evidence DCN sequencing plus light/electron microscopy and immunofluorescence of affected corneal tissue

   PMID:36534610

   Open questions at the time

   • Molecular mechanism by which the frameshift product perturbs fibril spacing not dissected
   • Whether the mutant acts dominant-negatively or via haploinsufficiency unresolved
8. 2024 Medium

   Showed DCN loss in stromal fibroblasts drives a cancer-associated fibroblast phenotype via STAT3/AUF1, identifying a paracrine pro-tumor mechanism reversible by DCN restoration.

   Evidence DCN knockdown/overexpression in breast stromal fibroblasts with signaling, co-culture, and orthotopic tumor assays

   PMID:38667295

   Open questions at the time

   • Direct link between DCN and STAT3/AUF1 (receptor/upstream node) not defined
   • Whether secreted DCN acts cell-autonomously or via matrix not separated
9. 2024 Medium

   Placed DCN within host defense by showing PGRN/mTOR signaling represses DCN to suppress autophagy and permit H. pylori colonization.

   Evidence H. pylori infection models with PGRN/DCN overexpression and knockdown plus mTOR inhibition

   PMID:39145305

   Open questions at the time

   • Mechanism by which DCN promotes autophagy not defined
   • Direct PGRN-DCN regulatory step versus indirect mTOR effect not separated
10. 2025 Medium

    Identified EGR3 as a direct transcriptional activator of DCN, linking an upstream transcription factor to DCN's tumor-suppressive program in liver cancer.

    Evidence ChIP and luciferase reporter assays with EGR3 knockdown and DCN rescue in liver cancer cells

    PMID:40660758

    Open questions at the time

    • Whether EGR3 regulation of DCN operates in non-hepatic contexts unknown
    • Upstream signals controlling EGR3 here not defined
11. 2025 Medium

    Showed DCN confers cytoprotection against oxidative injury by acting upstream of HIF1A to support survival and regulate autophagy.

    Evidence DCN overexpression/knockdown in H2O2-injured hepatocytes with HIF1A inhibitor (LW6) rescue

    PMID:41468793

    Open questions at the time

    • Mechanism connecting DCN to HIF1A stabilization not defined
    • Receptor mediating the cytoprotective signal unidentified
12. 2025 Low

    Extended DCN's structural role to tendon repair, demonstrating it promotes stem cell differentiation and ordered collagen fibril formation.

    Evidence In vitro TSC assays and in vivo Achilles tendon repair with DCN/heparin-loaded sutures

    PMID:41313163

    Open questions at the time

    • Molecular target of DCN in tendon not identified
    • Contribution of heparin co-delivery versus DCN alone not separated

• The cell-surface receptor(s) and signaling logic that unify DCN's anti-fibrotic, anti-tumor, cytoprotective, and immune-activating functions across tissues remain undefined.
• No single mechanistic model reconciling EGFR antagonism, AGER signaling, and HIF1A/AMPK cytoprotection
• Structural basis of DCN-receptor interactions not resolved in this corpus
• Quantitative relationship between matrix-bound and soluble DCN pools unknown